At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Trading 05-28 14:53:56
14.090
-0.910
-6.07%
High15.220Low14.080Vol1.42M
Open15.100D1 Closing15.000Amplitude7.60%
Mkt Cap14.95BTradable Cap14.95BTotal Shares1.06B
T/O20.64MT/O Rate0.13%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
ASCLETIS-B Shares Surge Over 5% in Early Trading as GIC Boosts Stake to 7% and U.S. Phase II Study Completes Enrollment
Stock News  ·  05-21
ASCLETIS-B Shares Surge Over 5% in Early Trading as GIC Boosts Stake to 7% and U.S. Phase II Study Completes Enrollment
GIC Private Limited Increases Stake in Ascletis-B (01672) by 122,000 Shares at HK$16.612 Each
Stock News  ·  05-12
GIC Private Limited Increases Stake in Ascletis-B (01672) by 122,000 Shares at HK$16.612 Each
Citigroup: Fundamentals of China's Healthcare Sector Show Sustained Improvement, Top Picks Include WuXi AppTec (02359)
Stock News  ·  05-11
Citigroup: Fundamentals of China's Healthcare Sector Show Sustained Improvement, Top Picks Include WuXi AppTec (02359)
HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%
Tiger Newspress  ·  05-11
HK Movers | Biotech Stocks Jump. InnoGen up over 44%; Clover Bio up over 11%; Junshi Bio up 9%; Laekna up 8%; Asymchem up over 3%; Tigermed up 2%
ASCLETIS-B Adds 0.24 Million Shares from Option Exercises; Public Float Remains Compliant
Bulletin Express  ·  05-07
ASCLETIS-B Adds 0.24 Million Shares from Option Exercises; Public Float Remains Compliant
Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations
Stock News  ·  05-06
Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations
ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)
Stock News  ·  05-06
ASCLETIS-B (01672) to Present Multiple Program Data at 33rd European Congress on Obesity (ECO 2026)
Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone
Bulletin Express  ·  05-06
Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone
Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026
Reuters  ·  05-06
Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026
ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations
Stock News  ·  04-30
ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations
ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions
Stock News  ·  04-30
ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
prnewswire  ·  04-30
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study
Reuters  ·  04-30
Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study
歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进
Bulletin Express  ·  04-29
歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进
HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%
Tiger Newspress  ·  04-28
HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%
Sagimet Biosciences Shares Rise With Focus on Acne Treatment
Dow Jones  ·  04-27
Sagimet Biosciences Shares Rise With Focus on Acne Treatment
ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes
Stock News  ·  04-27
ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes
Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes
THOMSON REUTERS  ·  04-27
Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes
Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30
Reuters  ·  04-27
Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30
ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial
Stock News  ·  04-24
ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--